Literature DB >> 28861666

Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry.

Birthe Krogh Rasmussen1, Steinbjørn Hansen2,3, René J Laursen4, Michael Kosteljanetz5, Henrik Schultz6, Bente Mertz Nørgård7,8, Rikke Guldberg7,8, Kim Oren Gradel7,8.   

Abstract

In this national population-based study of glioma, we present epidemiologic data on incidence, demographics, survival, clinical characteristics and symptoms, and evaluate the association of specific indicators with the grade of glioma. We included 1930 patients registered in the Danish Neuro-Oncology Registry (DNOR) from 2009 to 2014. DNOR is a large-scale national population-based database including all adult glioma patients in Denmark. The age-adjusted annual incidence of histologic verified glioma was 7.3 cases pr. 100,000 person-years. High-grade gliomas were present in 85% and low-grade glioma in 15%. The overall male:female ratio was 3:2 and the mean age at onset was 60 years. Data for WHO grade I, II, III and IV glioma showed several important differences regarding age and sex distribution and symptomatology at presentation. The mean age increased with the grade of glioma and males predominated in all grades. Focal deficits were the most frequent presenting symptom, but among patients with glioma, grade II epileptic seizures were the most frequent symptom. Headache was a rare mono-symptomatic onset symptom. At presentation, higher age, focal deficits and cognitive change for <3 months duration, and headache <1 month were significant independent indicators of high-grade gliomas. Younger age and epileptic seizures for more than 3 months were indicative for low-grade gliomas. Survival rates for glioma grade I-IV showed decreasing survival with increasing grade. Glioma grade I-IV showed high diversity regarding several demographic and clinical characteristics emphasizing the importance of individually tailored disease treatments and support.

Entities:  

Keywords:  Epidemiology; Glioma; Prognosis; Survival; Symptoms

Mesh:

Year:  2017        PMID: 28861666     DOI: 10.1007/s11060-017-2607-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  Mobile phone use and incidence of glioma in the Nordic countries 1979-2008: consistency check.

Authors:  Isabelle Deltour; Anssi Auvinen; Maria Feychting; Christoffer Johansen; Lars Klaeboe; Risto Sankila; Joachim Schüz
Journal:  Epidemiology       Date:  2012-03       Impact factor: 4.822

2.  Prior hospitalization for epilepsy, diabetes, and stroke and subsequent glioma and meningioma risk.

Authors:  Judith Schwartzbaum; Fredrik Jonsson; Anders Ahlbom; Susan Preston-Martin; Beatrice Malmer; Stefan Lönn; Karin Söderberg; Maria Feychting
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-03       Impact factor: 4.254

3.  A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.

Authors:  Rikke H Dahlrot; Bjarne W Kristensen; Jacob Hjelmborg; Jørn Herrstedt; Steinbjørn Hansen
Journal:  Int J Clin Exp Pathol       Date:  2012-11-20

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

Review 5.  Epidemiology of gliomas.

Authors:  Quinn T Ostrom; Haley Gittleman; Lindsay Stetson; Selene M Virk; Jill S Barnholtz-Sloan
Journal:  Cancer Treat Res       Date:  2015

6.  Clinical features of primary brain tumours: a case-control study using electronic primary care records.

Authors:  William Hamilton; David Kernick
Journal:  Br J Gen Pract       Date:  2007-09       Impact factor: 5.386

7.  Incidences of gliomas and meningiomas in Denmark, 1943 to 1997.

Authors:  Helle Collatz Christensen; Michael Kosteljanetz; Christoffer Johansen
Journal:  Neurosurgery       Date:  2003-06       Impact factor: 4.654

8.  A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).

Authors:  Rikke H Dahlrot; Bjarne W Kristensen; Jacob Hjelmborg; Jørn Herrstedt; Steinbjørn Hansen
Journal:  J Neurooncol       Date:  2013-07-02       Impact factor: 4.130

Review 9.  Headaches and brain tumors.

Authors:  Sarah Kirby; R Allan Purdy
Journal:  Neurol Clin       Date:  2013-12-27       Impact factor: 3.806

Review 10.  The Danish Neuro-Oncology Registry.

Authors:  Steinbjørn Hansen
Journal:  Clin Epidemiol       Date:  2016-10-25       Impact factor: 4.790

View more
  68 in total

1.  Neural stem cells promote glioblastoma formation in nude mice.

Authors:  J Wang; J Liu; H Meng; Y Guan; Y Yin; Z Zhao; G Sun; A Wu; L Chen; X Yu
Journal:  Clin Transl Oncol       Date:  2019-04-03       Impact factor: 3.405

2.  Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases.

Authors:  Avi Leader; Eva N Hamulyák; Brian J Carney; Maya Avrahami; Jelijn J Knip; Shira Rozenblatt; Ludo F M Beenen; Shlomit Yust-Katz; Oded Icht; Michiel Coppens; Pia Raanani; Saskia Middeldorp; Harry R Büller; Jeffrey I Zwicker; Galia Spectre
Journal:  Blood Adv       Date:  2020-12-22

3.  Over-expression of TOP2A as a prognostic biomarker in patients with glioma.

Authors:  Tianmin Zhou; Yan Wang; Dongmeng Qian; Qing Liang; Bin Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

4.  Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV.

Authors:  Kristin Marie Knudsen-Baas; Tom Børge Johannesen; Tor Åge Myklebust; Jan Harald Aarseth; Jone Furlund Owe; Nils Erik Gilhus; Anette Margrethe Storstein
Journal:  J Neurooncol       Date:  2018-11-23       Impact factor: 4.130

5.  MicroRNA-206 attenuates glioma cell proliferation, migration, and invasion by blocking the WNT/β-catenin pathway via direct targeting of Frizzled 7 mRNA.

Authors:  Fengqi Zhou; Wenping Cao; Ran Xu; Junxia Zhang; Tianfu Yu; Xiupeng Xu; Tongle Zhi; Jianxing Yin; Shengwu Cao; Ning Liu; Yingyi Wang; Chunsheng Zhao
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

6.  Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014.

Authors:  Steinbjørn Hansen; Birthe Krogh Rasmussen; René Johannes Laursen; Michael Kosteljanetz; Henrik Schultz; Bente Mertz Nørgård; Rikke Guldberg; Kim Oren Gradel
Journal:  J Neurooncol       Date:  2018-05-12       Impact factor: 4.130

7.  Prediagnostic symptoms and signs of adult glioma: the patients' view.

Authors:  Marthe C M Peeters; Linda Dirven; Johan A F Koekkoek; Ellen G Gortmaker; Lara Fritz; Maaike J Vos; Martin J B Taphoorn
Journal:  J Neurooncol       Date:  2020-01-01       Impact factor: 4.130

Review 8.  Potential role of microRNAs as biomarkers in human glioblastoma: a mini systematic review from 2015 to 2020.

Authors:  Manuela Rocha de Menezes; Maria Eduarda Azevêdo Acioli; Ana Carolina Lemos da Trindade; Suéllen Pedrosa da Silva; Raul Emídio de Lima; Vanessa Gabryelle da Silva Teixeira; Luydson Richardson Silva Vasconcelos
Journal:  Mol Biol Rep       Date:  2021-05-25       Impact factor: 2.316

9.  The Influence of NDRG1 Single Nucleotide Polymorphisms on Glioma Risk and Prognosis in Chinese Han Population.

Authors:  Yonghui Yang; Yimin Cheng; Liting Yang; Guangyao Shi; Peng Chen; Liang Li; Hangrong Fang; Chao Chen; Tianbo Jin
Journal:  Cell Mol Neurobiol       Date:  2021-03-12       Impact factor: 5.046

Review 10.  The Acidic Brain-Glycolytic Switch in the Microenvironment of Malignant Glioma.

Authors:  Anna Maria Reuss; Dominik Groos; Michael Buchfelder; Nicolai Savaskan
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.